Free Trial
NASDAQ:RAPP

Rapport Therapeutics 8/8/2024 Earnings Report

Rapport Therapeutics logo
$8.40 -0.11 (-1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$8.22 -0.18 (-2.08%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rapport Therapeutics EPS Results

Actual EPS
-$1.70
Consensus EPS
-$0.68
Beat/Miss
Missed by -$1.02
One Year Ago EPS
N/A

Rapport Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rapport Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rapport Therapeutics' Q2 2025 earnings is scheduled for Monday, June 2, 2025

Conference Call Resources

Rapport Therapeutics Earnings Headlines

Dalio heeds Buffett’s warning… [$319 million stake in gold]
Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks.
See More Rapport Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rapport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your email.

About Rapport Therapeutics

Rapport Therapeutics (NASDAQ:RAPP) Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

View Rapport Therapeutics Profile

More Earnings Resources from MarketBeat